Premium
Treatment of metastatic Ewing's sarcoma with BCNU
Author(s) -
Palma Jaime,
Gailani Salman,
Freeman Arnold,
Sinks Lucius,
Holland James F.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197210)30:4<909::aid-cncr2820300408>3.0.co;2-y
Subject(s) - medicine , micrometastasis , sarcoma , carmustine , chemotherapy , subclinical infection , adjuvant chemotherapy , adjuvant , surgery , metastasis , oncology , cancer , pathology , etoposide , breast cancer
Twelve patients with metastatic Ewing's sarcoma, ranging in age from 4 to 26 years, were treated with 1‐3‐bis chloroethyl nitrosourea (BCNU). The tumor in five of the patients showed objective tumor shrinkage with BCNU. In one patient, there was complete disappearance of the tumor lasting 21/2 years. In four other patients, there was partial improvement (50% shrinkage) lasting 2, 3, 6, and 8 months. BCNU may be of value in an adjuvant chemotherapy program as part of the initial treatment in an attempt to eradicate subclinical micrometastasis and thus increase the cure rate.